Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF | V.TLT.WT

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by ScienceFirston Jan 17, 2023 5:39pm
280 Views
Post# 35229295

RE:RE:RE:Buyouts - USD or CAD

RE:RE:RE:Buyouts - USD or CADPlantrader ...  The best way for you to understand biotechs market valuations on takeovers or on jv is to look to different news.  

Ballpark estimates, based on what we often see for disruptive technologies:

- If TLT was only a one-indication biotech that was to become the SOC for NMIBC, it would be acquired for approx. 3B$US, given the size of the NMIBC market and assuming 284M fully diluted shares.

- If TLT was to be successful in both NMIBC, (FDA approval) and GBM (Ph. 1b) and NSCLC (Ph. 1b) plus a portfolio of PDCs, it would be acquired for approx. 12B$US+, , assuming 284M fully diluted shares, considering the demonstration that PDT delivers on more than one type of indications, on complex ones, in late-stage ones and in more than one field of specilaties (urology, neurology, pulmonary).

- In the meantime, a jv with a big pharma on NMIBC would bring us easily above the 500M$US with a FDA Breakthough Therapy designation and around 1.5B$US+ with an Accelerated Approval.  Breakthrough Therapy would require us to complete the Ph. 2 before collecting revenues as Accelerated Approval would allow us to collect revenues immediately and would, for sure, attract a big pharma for a jv right.

Since 2016, TLT's plan has always been to jv on its first indication and then confirm efficacy on a Ph. 1b for the next 2 indications in order to demonstrate to full potential of the PDT#PDC technology before being acquired by selling with it, its PDC portfolio, so the acquirer can bring more indications under the PDT/PDC.  That's exactly the plan TLT is executing, and it has been outlined once again in the Jan. 3rd article.

A jv for NMIBC rights would bring us upfront payments that could finance GBM and NSCLC Ph. 1b trials.

____________

RE:RE:Buyouts - USD or CAD
N0taP00p wrote:Theralase uses USD for their $1.1B to $1.7B revenue opportunity projections. So I'm guessing we're all using USD. 


$3B USD would be juicyyyyyyyy

<< Previous
Bullboard Posts
Next >>